Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer

Hiroshi Hongo, Takeo Kosaka, Mototsugu Oya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An 80-year-old man with an elevated prostate-specific antigen (PSA) level of 120 ng/mL) presented to the hospital in February 2011. A prostate needle biopsy was performed, and pathological examination revealed prostatic adenocarcinoma. The Gleason score was 4+5=9. Computed tomography revealed metastases of the pelvic lymph nodes. Combined androgen blockade was started. The PSA concentration decreased to 1.68 ng/mL, but started increasing again in August 2012 to 6.08 ng/mL. Although bicalutamide was discontinued due to antiandrogen withdrawal syndrome, the PSA concentration increased even more. The PSA concentration reached 21.62 ng/mL in September 2012, at which time ethnylestradiol was started. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2 years. To our knowledge, this is first case report describing a complete response to ethnylestradiol that lasted for almost 2 years in a patient with castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)e921-e923
JournalJournal of the Canadian Urological Association
Volume8
Issue number11-12 DECEMBER
DOIs
Publication statusPublished - 2014 Dec 1

Fingerprint

Castration
Prostate-Specific Antigen
Prostatic Neoplasms
Androgen Antagonists
Neoplasm Grading
Needle Biopsy
Androgens
Prostate
Adenocarcinoma
Lymph Nodes
Tomography
Neoplasm Metastasis

Keywords

  • Androgen
  • Androgen receptor
  • Estrogen
  • Ethnylestradiol
  • Prostate cancer
  • Prostate specific antigen

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{0d3d2432d28b471fbad116b5991861c1,
title = "Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer",
abstract = "An 80-year-old man with an elevated prostate-specific antigen (PSA) level of 120 ng/mL) presented to the hospital in February 2011. A prostate needle biopsy was performed, and pathological examination revealed prostatic adenocarcinoma. The Gleason score was 4+5=9. Computed tomography revealed metastases of the pelvic lymph nodes. Combined androgen blockade was started. The PSA concentration decreased to 1.68 ng/mL, but started increasing again in August 2012 to 6.08 ng/mL. Although bicalutamide was discontinued due to antiandrogen withdrawal syndrome, the PSA concentration increased even more. The PSA concentration reached 21.62 ng/mL in September 2012, at which time ethnylestradiol was started. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2 years. To our knowledge, this is first case report describing a complete response to ethnylestradiol that lasted for almost 2 years in a patient with castration-resistant prostate cancer.",
keywords = "Androgen, Androgen receptor, Estrogen, Ethnylestradiol, Prostate cancer, Prostate specific antigen",
author = "Hiroshi Hongo and Takeo Kosaka and Mototsugu Oya",
year = "2014",
month = "12",
day = "1",
doi = "10.5489/cuaj.2293",
language = "English",
volume = "8",
pages = "e921--e923",
journal = "Journal of the Canadian Urological Association",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "11-12 DECEMBER",

}

TY - JOUR

T1 - Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer

AU - Hongo, Hiroshi

AU - Kosaka, Takeo

AU - Oya, Mototsugu

PY - 2014/12/1

Y1 - 2014/12/1

N2 - An 80-year-old man with an elevated prostate-specific antigen (PSA) level of 120 ng/mL) presented to the hospital in February 2011. A prostate needle biopsy was performed, and pathological examination revealed prostatic adenocarcinoma. The Gleason score was 4+5=9. Computed tomography revealed metastases of the pelvic lymph nodes. Combined androgen blockade was started. The PSA concentration decreased to 1.68 ng/mL, but started increasing again in August 2012 to 6.08 ng/mL. Although bicalutamide was discontinued due to antiandrogen withdrawal syndrome, the PSA concentration increased even more. The PSA concentration reached 21.62 ng/mL in September 2012, at which time ethnylestradiol was started. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2 years. To our knowledge, this is first case report describing a complete response to ethnylestradiol that lasted for almost 2 years in a patient with castration-resistant prostate cancer.

AB - An 80-year-old man with an elevated prostate-specific antigen (PSA) level of 120 ng/mL) presented to the hospital in February 2011. A prostate needle biopsy was performed, and pathological examination revealed prostatic adenocarcinoma. The Gleason score was 4+5=9. Computed tomography revealed metastases of the pelvic lymph nodes. Combined androgen blockade was started. The PSA concentration decreased to 1.68 ng/mL, but started increasing again in August 2012 to 6.08 ng/mL. Although bicalutamide was discontinued due to antiandrogen withdrawal syndrome, the PSA concentration increased even more. The PSA concentration reached 21.62 ng/mL in September 2012, at which time ethnylestradiol was started. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2 years. To our knowledge, this is first case report describing a complete response to ethnylestradiol that lasted for almost 2 years in a patient with castration-resistant prostate cancer.

KW - Androgen

KW - Androgen receptor

KW - Estrogen

KW - Ethnylestradiol

KW - Prostate cancer

KW - Prostate specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84919928527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919928527&partnerID=8YFLogxK

U2 - 10.5489/cuaj.2293

DO - 10.5489/cuaj.2293

M3 - Article

VL - 8

SP - e921-e923

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

SN - 1911-6470

IS - 11-12 DECEMBER

ER -